Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939237 · ClinicalTrials.gov registry record · Phase 3
Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 213
- Enrollment target
NCT00939237 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 213 participants.
The verdict
NCT00939237, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Ateronon, a nutritional supplement that contains lycopene from tomatoes has a favorable effect on carotid atherosclerosis, lipid levels, and other biomarkers of coronary heart disease. The trial was stopped early due to insufficient financial support from the initial study collaborator, Cambridge Theranostics Ltd. Collected patient data are sufficient for final trial-based analyses to be conducted with financial support from the new study collaborator, CamNutra Ltd. The data will still be analyzed according to the original study aims.
Interventions
- DRUG Placebo
- DRUG Ateronon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939237
The ClinicalTrials.gov registry entry for NCT00939237 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00939237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939237 about?
NCT00939237 is a clinical study titled "Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease". The purpose of this study is to determine whether Ateronon, a nutritional supplement that contains lycopene from tomatoes has a favorable effect on carotid atherosclerosis, lipid levels, and other biomarkers of coronary heart disease. The trial was stopped early due to insufficient financial suppor...
What is the current status of trial NCT00939237?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 213 participants. The study started on 2009-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00939237?
The interventions under investigation include: Placebo (DRUG), Ateronon (DRUG).
Who is sponsoring clinical trial NCT00939237?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.